🇯🇵·15h agoIndustry
Santen Obtains Marketing Approval in the Philippines for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia — First Approval in Santen’s Asia Business Region
Publisher
S
Santen Pharmaceutical
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Santen Pharmaceutical
- Region
- Japan
- Scope
- Industry
- Published
- June 26, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on santen.com
Leave the platform to read the original full article on the publisher site.
Source: Santen Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Eli Lilly News/4h ago
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Eli Lilly News/7h ago
Lilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories through GenAI
Darnitsa (Ukraine)/8h ago
Cough & cold
Darnitsa (Ukraine)/8h ago